Carzenide is an antispasmodic that has been used in the treatment of dysmenorrhoea. Currently Carzenide is an organic synthesis intermediate, used for synthetic drug.

Metoserpate (SU9064) is a sedative drug used in veterinary. PACITRAN (metoserpate hydrochloride) is indicated as a tranquilizer in stressed poultry.

Piquizil, a 4-aminoquinazoline causing relaxation of respiratory smooth muscle in animals, appeared to be a bronchodilator in man. It has been shown to be equal in activity to a combination of theophylline, ephedrine and phenobarbital. Piquizil and Tedral were equally effective in the management of asthmatic patients.

Disofenin is an iminodiacetic acid derivative with no known pharmacologic actions at the doses recommended. Technetium Tc 99m disofenin injection is a radiopharmaceutical. Technetium Tc99m disofenin is indicated as a hepatobiliary imaging agent. Technetium Tc99m disofenin is indicated in the diagnosis of acute cholecystitis as well as to rule out the occurrence of acute cholecystitis in suspected patients with right upper quadrant pain, fever, jaundice, right upper quadrant tenderness and mass or rebound tenderness, but not limited to these signs and symptoms. Itching at the site of injection progressing to erythema multiforme has been reported following single administration. Also, rare cases of chills and nausea have been reported.

Thyromedan is a thyroalkanoic acid derivative with hypocholesterolemic activity. In clinical trials, Thyromedan in daily doses of 8 to 32 mg caused a decrease in serum cholesterol levels. The serum total triglycerides and the α- and β-lipoprotein partition of cholesterol and triglycerides were unaffected.

Iodometomidate I-123, R- (also known as ) is phenylethylimidazole derivative studied as a diagnostic agent for adrenal imaging. Iodometomidate is a highly suitable tracer combining specific uptake in adrenocortical tissue with far lower radiation exposure compared to norcholesterol scintigraphy. Phase III clinical trial for Adrenal Gland Neoplasms imaging is currently ongoing.

SR 202 is an antagonist of peroxisome proliferator-activated receptor γ (PPARγ) transcriptional activity induced by troglitazone but not of basal PPARγ activity. It is selective for PPARγ, not affecting basal or agonist-induced transcriptional activity of PPARα, PPARβ, or the farnesoid X receptor (FXR). It inhibits PPARγ-dependent differentiation of preadipocyte 3T3-L1 cells in a dose-dependent manner. SR 202 (400 mg/kg) decreases the amount of weight gained and white adipose tissue mass accumulated by mice fed a standard or high-fat diet for ten weeks and is associated with lower PPARγ mRNA levels. It protects against high-fat diet-induced insulin resistance in wild-type mice and improves insulin sensitivity in ob/ob mice.